ELOVL5: A Protein Involved in Endoplasmic Reticulum Function and Disease

Target Name: ELOVL5

NCBI ID: G60481

ELOVL5

ELOVL5: A Protein Involved in Endoplasmic Reticulum Function and Disease

ELOVL5 (Endoplasmic Reticulum-Localized Voltage-Gated Calcium Ion Channel) is a protein that is expressed in various tissues and cells in the body. It is a member of the voltage-gated calcium ion channel (Ca2+ channel) family, which is a subclass of ion channels that regulate the flow of calcium ions into and out of cells. ELOVL5 is unique in that it is localized to the endoplasmic reticulum, which is the membrane-bound fraction of the endoplasmic complex that separates the cytoplasm from the endoplasmic cleavage complex.

The endoplasmic reticulum is a specialized organell that functions as the final destination for the proteins synthesized by the ribosome. It is responsible for processing and modifying these proteins, as well as for maintaining the cytoskeleton and organizing the cell. The endoplasmic reticulum is also the site of intracellular signaling, where various signaling pathways are activated and regulated.

ELOVL5 is a key protein that is involved in several cellular processes, including intracellular signaling, protein folding, and cell signaling. Its unique localization to the endoplasmic reticulum makes it an attractive drug target and a potential biomarker for several diseases.

Diseases that are characterized by the over-expression or under-expression of ELOVL5 include neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as diseases that are characterized by the misfolding of proteins, such as amyloidosis and Huntington's disease. These diseases are caused by the accumulation of misfolded proteins in the endoplasmic reticulum, which can lead to a build-up of toxic aggregates that cause damage to the brain and other tissues.

In addition to its involvement in neurodegenerative diseases, ELOVL5 is also a potential drug target for several other diseases. For example, ELOVL5 has been shown to be involved in the regulation of pain signaling, and may be a potential drug target for chronic pain. It is also involved in the regulation of cell signaling, and may be a potential drug target for diseases that are characterized by the misfolding of proteins, such as cancer.

The ability of ELOVL5 to localize to the endoplasmic reticulum makes it an attractive drug target for several reasons. Firstly, drugs that can inhibit the activity of ELOVL5 will have a more limited impact on cells than drugs that target other parts of the endoplasmic reticulum, such as the outer membrane or the cytoskeleton. Secondly, drugs that can inhibit the activity of ELOVL5 will have a more persistent effect than drugs that have a more rapid and short-lived impact on the endoplasmic reticulum.

Another potential mechanism by which ELOVL5 may be targeted by drugs is its role in intracellular signaling. ELOVL5 is involved in several intracellular signaling pathways, including the regulation of protein folding, the regulation of cell signaling, and the regulation of intracellular signaling pathways. Drugs that can inhibit the activity of ELOVL5 may have a more targeted impact on these signaling pathways, and may be more effective at treating diseases that are characterized by the over-expression or under-expression of ELOVL5.

In conclusion, ELOVL5 is a protein that is involved in several cellular processes that are important for the function of the endoplasmic reticulum. Its unique localization to the endoplasmic reticulum makes it an attractive drug target for several diseases, including neurodegenerative diseases, diseases characterized by the misfolding of proteins, and chronic pain. The ability of ELOVL5 to regulate intracellular signaling pathways also makes it a potential drug target for diseases that are characterized by the over-expression or under-expression of ELOVL5. Further research is needed to

Protein Name: ELOVL Fatty Acid Elongase 5

Functions: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that acts specifically toward polyunsaturated acyl-CoA with the higher activity toward C18:3(n-6) acyl-CoA. May participate in the production of monounsaturated and of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators (By similarity) (PubMed:10970790, PubMed:20937905). In conditions where the essential linoleic and alpha linoleic fatty acids are lacking it is also involved in the synthesis of Mead acid from oleic acid (By similarity)

The "ELOVL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOVL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets